Pharmaceutical Preparations · DE · CIK 1637715
Develops precision medicines targeting specific cancer mutations for improved efficacy and tolerability
Comparable business profile · signals at a glance
In the 90 days to Mar 23, 2026: 2 sold $2K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 23, 2026 | Leverone Jason A.Chief Financial Officer | Sell | 301 | $4.16 | $1K |
| Mar 23, 2026 | Saccomano Nicholas APresident and CEO | Sell | 86 | $4.16 | $358 |
| Dec 22, 2025 | Leverone Jason A.Chief Financial Officer | Sell | 302 | $2.97 | $897 |
| Dec 22, 2025 | Saccomano Nicholas APresident and CEO | Sell | 87 | $2.97 | $258 |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.